arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2019-25-5-568-576arthyper-1913Research ArticleСтатьиArticlesВлияние ожирения, нарушения углеводного обмена и бариатрической хирургии на уровни мРНК адипонектина и лептина в различных депо жировой тканиThe effect of obesity, impaired carbohydrate metabolism and bariatric surgery on adiponectin and leptin mRNA levels in different adipose tissue depotsВасильеваЛ. Б.VasilevaL. B.

Васильева Людмила Борисовна — младший научный сотрудник Группы клеточной биологии Института молекулярной биологии и генетики.

Санкт-Петербург

Vasileva L. Borisovna - Junior Researcher, Group of Cell Biology, Institute of Molecular Biology and Genetics.

St Petersburg

АртемьеваМ. С.ArtemyevaM. S.

Артемьева Марина Сергеевна — младший научный сотрудник НИЛ хирургии метаболических нарушений Института эндокринологии.

Санкт-Петербург

Marina S. Artemyeva - MD, Endocrinologist, Junior Researcher, Laboratory of Surgery of Metabolic Disorders.

St Petersburg

МаИ.MaYi.

Ма И — кандидат медицинских наук, младший научный сотрудник НИЛ трансфузиологии и эфферентной терапии Института онкологии и гематологии.

Санкт-Петербург

Ma Yi - MD, PhD, Junior Researcher, Laboratory of Transfusion and Efferent Therapy, Institute of Oncology and Hematology.

КондратовК. А.KondratovK. A.

Кондратов Кирилл Александрович — кандидат биологических наук, старший научный сотрудник НИЛ молекулярноклеточных механизмов атеросклероза Института молекулярной биологии и генетики.

Санкт-Петербург

Kirill A. Kondratov - MD, PhD, Senior Researcher, Laboratory of Molecular and Cellular Mechanisms of Atherosclerosis, Institute of Molecular Biology and Genetics.

St Petersburg

АноповаА. Д.AnopovaA. D.

Анопова Анна Дмитриевна — клинический ординатор.

Санкт-Петербург

Anna D. Anopova - MD, Clinical Resident.

St Petersburg

НеймаркА. Е.NeymarkA. E.

Неймарк Александр Евгеньевич—кандидат медицинских наук, заведующий НИЛ хирургии метаболических нарушений.

Санкт-Петербург

Alexander E. Neymark - MD, PhD, Head, Laboratory of Surgery of Metabolic Disorders Almazov NMRC, President, Russian Society of Bariatric Surgeons.

St Petersburg

БабенкоА. Ю.BabenkoA. Yu.

Бабенко Алина Юрьевна — доктор медицинских наук, заведующая НИЛ диабетологии Института эндокринологии ФГБУ «НМИЦ им. В. А. Алмазова» МР, доцент кафедры терапии факультетской с курсом эндокринологии имени Г. Ф. Ланга ГБОУ ВПО ПСПбГМУ им. И. П. ПМРоссии.

Санкт-Петербург

Alina Yu. Babenko - MD, PhD, DSc, Head, Laboratory of Diabetology, Almazov NMRC; Associate Professor, Department of Internal Diseases № 2 with the Course of Endocrinology n. a. G. F. Lang, First Pavlov State Medical University of St. Petersburg

ФедоровA. В.FedorovA. V.

Федоров Антон Владимирович—кандидат биологических наук, заведующий НИЛ молекулярно-клеточных механизмов атеросклероза Института молекулярной биологии и генетики.

Ул. Аккуратова, д. 2, Санкт-Петербург, 197341, Тел.: 8(812)702-37-77

Anton V Fedorov - PhD, Head, Laboratory of Molecular and Cellular Mechanisms of Atherosclerosis, Institute of Molecular Biology and Genetics.

2 Akkuratov street, St Petersburg, 197341

antonfedorow@gmail.comФГБУ Национальный медицинский исследовательский центр имени В.А. Алмазова Минздрава РоссииРоссияAlmazov National Medical Research CentreRussian Federation201931012020255568576Copyright © Васильева Л.Б., Артемьева М.С., Ма И., Кондратов К.А., Анопова А.Д., Неймарк А.Е., Бабенко А.Ю., Федоров A.В., 20202020Васильева Л.Б., Артемьева М.С., Ма И., Кондратов К.А., Анопова А.Д., Неймарк А.Е., Бабенко А.Ю., Федоров A.В.Vasileva L.B., Artemyeva M.S., Ma Y., Kondratov K.A., Anopova A.D., Neymark A.E., Babenko A.Y., Fedorov A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/1913

Цель исследования — определить влияние морбидного ожирения, нарушения углеводного обмена (НУО) и бариатрической хирургии на уровни мРНК адипонектина и лептина в подкожной и висцеральной жировой ткани.

Материалы и методы

Материалы и методы. В исследование было включено 30 пациентов женского пола с ожирением. У 11 пациентов ожирению сопутствовало нарушение углеводного обмена. Группу контроля составили 10 практически здоровых женщин без ожирения. У всех пациентов с ожирением забор подкожной и висцеральной жировой ткани осуществлялся во время бариатрической операции. У пациентов с ожирением через 1 год после вмешательства и индивидуумов из группы контроля осуществлялся забор подкожной жировой ткани. Уровни циркулирующих в крови белков адипонектина и лептина определяли иммуноферментным методом. Количество мРНК адипонектина и лептина в жировой ткани анализировали с помощью полимеразной цепной реакции в реальном времени.

Результаты

Результаты. В течение первого послеоперационного года у всех пациентов наблюдалось монотонное снижение индекса массы тела. После операции уровни циркулирующих в крови адипонектина и лептина вернулись к референсным значениям для здоровой популяции. По сравнению с контрольной группой, у пациентов с ожирением в подкожной жировой ткани уровень мРНК адипонектина понижен в 1,4 раза (р < 0,01), а уровень мРНК лептина не изменен. В висцеральной жировой ткани пациентов с ожирением и НУО уровень мРНК адипонекти-на понижен в 2 раза (р < 0,01), по сравнению с пациентами без НУО. Как у пациентов с ожирением, так и у пациентов с ожирением и НУО, в висцеральной жировой ткани, по сравнению с подкожной, уровни мРНК обоих адипокинов понижены более чем в 2 раза (р < 0,05). В подкожной жировой ткани через 1 год после бариатрического вмешательства уровень мРНК адипонектина понижается в 4,5 раза (р < 0,01) у пациентов с ожирением, а уровень мРНК лептина понижается в 3,1 раза (р < 0,01) у пациентов с ожирением и в 1,5 раза (р < 0,05) у пациентов с ожирением и НУО. Ни для адипонектина, ни для лептина не обнаружено статистически значимых связей между уровнями их мРНК из жировой ткани различной локализации. Также не обнаружено статистически значимых связей между уровнями белковых продуктов исследуемых адипокинов в крови и их экспрессией на уровне мРНК в жировой ткани.

Заключение

Заключение. Результаты работы указывают на то, что уровни мРНК адипонектина и лептина в клетках жировой ткани зависят от локализации жировой ткани, наличия ожирения и НУО, а также меняются в ответ на бариа-трические вмешательства.

Objective

Objective. To determine the effect of morbid obesity, impaired carbohydrate metabolism and bariatric surgery on adiponectin and leptin mRNA levels in subcutaneous and visceral adipose tissue.

Design and methods

Design and methods. The study included 30 obese female patients. Eleven patients had co-existent impaired carbohydrate metabolism. The control group consisted of 10 healthy non-obese women. In all obese patients, subcutaneous and visceral adipose tissue samples were taken during bariatric surgery. In obese patients 1 year after the intervention and in control individuals subcutaneous adipose tissue samples were collected. The circulating levels of adiponectin and leptin were determined by the enzyme immunoassay. The amount of adiponectin and leptin mRNA in adipose tissue were analyzed by real-time polymerase chain reaction.

Results

Results. During the first postoperative year, all patients showed a monotonous decrease in body mass index. After the surgery, the circulating levels of adiponectin and leptin returned to reference values (for healthy population). Compared with the control group, obese patients showed 1,4-times lower adiponectin mRNA level (p < 0,01) in subcutaneous adipose tissue, while leptin mRNA level did not change. In obese patients with impaired carbohydrate metabolism, the adiponectin mRNA level was twice lower in visceral adipose tissue (p < 0,01), compared to patients without impaired carbohydrate metabolism. In obese patients with and without impaired carbohydrate metabolism, mRNA levels of adipokines were more than 2-times lower in visceral adipose tissue compared to subcutaneous adipose tissue (p < 0,05). In subcutaneous adipose tissue, 1 year after bariatric intervention, adiponectin mRNA level decreases by 4,5 times (p < 0,01) in obese patients, and leptin mRNA level decreases by 3,1 times (p < 0,01) in patients with obesity and by 1,5 times (p < 0,05) in patients with obesity and impaired carbohydrate metabolism. Neither adiponectin nor leptin mRNA levels from adipose tissue of different localization showed statistically significant correlation. No correlation was found between the levels of circulating adipokines and their mRNA amount in adipose tissue.

Conclusions

Conclusions. Our results indicate that adiponectin and leptin mRNA levels in adipose tissue cells depend on their localization in the body, as well as the presence of obesity and impaired carbohydrate metabolism. We also showed that adiponectin and leptin mRNA levels in adipose tissue change in response to bariatric surgery.

адипонектинлептиножирениенарушение углеводного обменаподкожная и висцеральная жировая тканьбариатрическая хирургияadiponectinleptinobesityimpaired carbohydrate metabolismsubcutaneous and visceral adipose tissuebariatric surgeryИсследование выполнено за счет гранта Российского научного фонда (проект № 17—75—30052)The study was supported by the grant of the Russian Science Foundation (project № 17—75—30052)ReferencesGBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377 (1):13-27. doi:10.1056/NEJMoa1614362GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med. 2017;377 (1):13-27. doi:10.1056/NEJMoa1614362Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89(6):2548-56.Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89(6):2548-56.Bluher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015;64(1):131-45. doi:10.1016/j.metabol.2014.10.016Bluher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015;64(1):131-45. doi:10.1016/j.metabol.2014.10.016Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004;50(9):1511-25.Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004;50(9):1511-25.Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941-6.Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8):941-6.Farooqi S, O’Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006;27(7):710-18.Farooqi S, O’Rahilly S. Genetics of obesity in humans. Endocr Rev. 2006;27(7):710-18.Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-5.Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86(5):1930-5.Lecke SB, Morsch DM, Spritzer PM. Leptin and adiponectin in the female life course. Braz J Med Biol Res. 2011 ;44 (5):381-7.Lecke SB, Morsch DM, Spritzer PM. Leptin and adiponectin in the female life course. Braz J Med Biol Res. 2011 ;44 (5):381-7.Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev. 2000;1(1):47-56.Bosello O, Zamboni M. Visceral obesity and metabolic syndrome. Obes Rev. 2000;1(1):47-56.Tchernof A. Visceral adipocytes and the metabolic syndrome. Nutr Rev. 2007;65(6 Pt 2):S24-9.Tchernof A. Visceral adipocytes and the metabolic syndrome. Nutr Rev. 2007;65(6 Pt 2):S24-9.Drolet R, Belanger C, Fortier M, Huot C, Mailloux J, Legare D et al. Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity (Silver Spring). 2009;17(3):424-30. doi:10.1038/oby.2008.555Drolet R, Belanger C, Fortier M, Huot C, Mailloux J, Legare D et al. Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity (Silver Spring). 2009;17(3):424-30. doi:10.1038/oby.2008.555Chen J, Pamuklar Z, Spagnoli A, Torquati A. Serum leptin levels are inversely correlated with omental gene expression of adiponectin and markedly decreased after gastric bypass surgery. Surg Endosc. 2012;26(5):1476-80. doi:10.1007/s00464-011-2059-5Chen J, Pamuklar Z, Spagnoli A, Torquati A. Serum leptin levels are inversely correlated with omental gene expression of adiponectin and markedly decreased after gastric bypass surgery. Surg Endosc. 2012;26(5):1476-80. doi:10.1007/s00464-011-2059-5Savu MK, Phillips SA, Oh DK, Park K, Gerlan C, Ciaral-di TP et al. Response of adiponectin and its receptors to changes in metabolic state after gastric bypass surgery: dissociation between adipose tissue expression and circulating levels. Surg Obes Relat Dis. 2009;5(2):172-80. doi:10.1016/j.soard.2008.08.013Savu MK, Phillips SA, Oh DK, Park K, Gerlan C, Ciaral-di TP et al. Response of adiponectin and its receptors to changes in metabolic state after gastric bypass surgery: dissociation between adipose tissue expression and circulating levels. Surg Obes Relat Dis. 2009;5(2):172-80. doi:10.1016/j.soard.2008.08.013Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393-411. doi:10.1146/annurev.med.051308.105148Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393-411. doi:10.1146/annurev.med.051308.105148Schoettl T, Fischer IP, Ussar S. Heterogeneity of adipose tissue in development and metabolic function. J Exp Biol. 2018;221 (Pt Suppl 1). pii: jeb162958. doi:10.1242/jeb.162958Schoettl T, Fischer IP, Ussar S. Heterogeneity of adipose tissue in development and metabolic function. J Exp Biol. 2018;221 (Pt Suppl 1). pii: jeb162958. doi:10.1242/jeb.162958Hatoum IJ, Kaplan LM. Advantages of percent weight loss as a method of reporting weight loss after Roux-en-Y gastric bypass. Obesity (Silver Spring). 2013;21(8):1519-25. doi:10.1002/oby.20186Hatoum IJ, Kaplan LM. Advantages of percent weight loss as a method of reporting weight loss after Roux-en-Y gastric bypass. Obesity (Silver Spring). 2013;21(8):1519-25. doi:10.1002/oby.20186Corcelles R, Boules M, Froylich D, Hag A, Daigle CR, Aminian A et al. Total weight loss as the outcome measure of choice after Roux-en-Y gastric bypass. Obes Surg. 2016;26(8):1794-8. doi:10.1007/s11695-015-2022-yCorcelles R, Boules M, Froylich D, Hag A, Daigle CR, Aminian A et al. Total weight loss as the outcome measure of choice after Roux-en-Y gastric bypass. Obes Surg. 2016;26(8):1794-8. doi:10.1007/s11695-015-2022-yYou T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab. 2005;288 (4):E741-7.You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab. 2005;288 (4):E741-7.Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18): 10697-703.Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996;271(18): 10697-703.Lonnqvist F, Arner P, Nordfors L, Schalling M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med. 1995;1(9):950-3.Lonnqvist F, Arner P, Nordfors L, Schalling M. Overexpression of the obese (ob) gene in adipose tissue of human obese subjects. Nat Med. 1995;1(9):950-3.Hube F, Lietz U, Igel M, Jensen PB, Tornqvist H, Joost HG et al. Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Horm Metab Res. 1996;28(12):690-3.Hube F, Lietz U, Igel M, Jensen PB, Tornqvist H, Joost HG et al. Difference in leptin mRNA levels between omental and subcutaneous abdominal adipose tissue from obese humans. Horm Metab Res. 1996;28(12):690-3.Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun. 2006;341 (2):549-56.Chen B, Lam KS, Wang Y, Wu D, Lam MC, Shen J et al. Hypoxia dysregulates the production of adiponectin and plasminogen activator inhibitor-1 independent of reactive oxygen species in adipocytes. Biochem Biophys Res Commun. 2006;341 (2):549-56.Magalang UJ, Cruff JP, Rajappan R, Hunter MG, Patel T, Marsh CB et al. Intermittent hypoxia suppresses adiponectin secretion by adipocytes. Exp Clin Endocrinol Diabetes. 2009;117 (3):129-34. doi:10.1055/s-2008-1078738Magalang UJ, Cruff JP, Rajappan R, Hunter MG, Patel T, Marsh CB et al. Intermittent hypoxia suppresses adiponectin secretion by adipocytes. Exp Clin Endocrinol Diabetes. 2009;117 (3):129-34. doi:10.1055/s-2008-1078738Wang B, Wood IS, Trayhurn P. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes. J Endocrinol. 2008;198(1):127-34. doi:10.1677/JOE-08-0156Wang B, Wood IS, Trayhurn P. Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes. J Endocrinol. 2008;198(1):127-34. doi:10.1677/JOE-08-0156Al-Anazi A, Parhar R, Saleh S, Al-Hijailan R, Inglis A, Al-Jufan M et al. Intracellular calcium and NF-kB regulate hypoxia-induced leptin, VEGF, IL-6 and adiponectin secretion in human adipocytes. Life Sci. 2018;212:275-284. doi: 10.1016/j.lfs.2018.10.014Al-Anazi A, Parhar R, Saleh S, Al-Hijailan R, Inglis A, Al-Jufan M et al. Intracellular calcium and NF-kB regulate hypoxia-induced leptin, VEGF, IL-6 and adiponectin secretion in human adipocytes. Life Sci. 2018;212:275-284. doi: 10.1016/j.lfs.2018.10.014Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004;219(1-2):9-15.Lihn AS, Bruun JM, He G, Pedersen SB, Jensen PF, Richelsen B. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004;219(1-2):9-15.Carmina E, Chu MC, Moran C, Tortoriello D, Vardhana P, Tena G et al. Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. Fertil Steril. 2008;89(3):642-8.Carmina E, Chu MC, Moran C, Tortoriello D, Vardhana P, Tena G et al. Subcutaneous and omental fat expression of adiponectin and leptin in women with polycystic ovary syndrome. Fertil Steril. 2008;89(3):642-8.Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res. 2000;1(2):81-8.Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res. 2000;1(2):81-8.Sirbu AE, Buburuzan L, Kevorkian S, Martin S, Barbu C, Copaescu C et al. Adiponectin expression in visceral adiposity is an important determinant of insulin resistance in morbid obesity. Endokrynol Pol. 2018;69(3):252-258. doi:10.5603/EP.a2018.0026Sirbu AE, Buburuzan L, Kevorkian S, Martin S, Barbu C, Copaescu C et al. Adiponectin expression in visceral adiposity is an important determinant of insulin resistance in morbid obesity. Endokrynol Pol. 2018;69(3):252-258. doi:10.5603/EP.a2018.0026Teijeira-Fernandez E, Eiras S, Grigorian-Shamagian L, Salgado-Somoza A, Martinez-Comendador JM, Gonzalez-Juana-tey JR. Diabetic and nondiabetic patients express similar adipose tissue adiponectin and leptin levels. Int J Obes (Lond). 2010;34 (7):1200-8. doi:10.1038/ijo.2010.30Teijeira-Fernandez E, Eiras S, Grigorian-Shamagian L, Salgado-Somoza A, Martinez-Comendador JM, Gonzalez-Juana-tey JR. Diabetic and nondiabetic patients express similar adipose tissue adiponectin and leptin levels. Int J Obes (Lond). 2010;34 (7):1200-8. doi:10.1038/ijo.2010.30Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun. 2001;288(5):1102-7.Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun. 2001;288(5):1102-7.Stolic M, Russell A, Hutley L, Fielding G, Hay J, MacDonald G et al. Glucose uptake and insulin action in human adipose tissue — influence of BMI, anatomical depot and body fat distribution. Int J Obes Relat Metab Disord. 2002;26(1):17-23.Stolic M, Russell A, Hutley L, Fielding G, Hay J, MacDonald G et al. Glucose uptake and insulin action in human adipose tissue — influence of BMI, anatomical depot and body fat distribution. Int J Obes Relat Metab Disord. 2002;26(1):17-23.Chen J, Spagnoli A, Torquati A. Omental gene expression of adiponectin correlates with degree of insulin sensitivity before and after gastric bypass surgery. Obes Surg. 2012;22(3):472-7. doi: 10.1007/s11695-011-0568-xChen J, Spagnoli A, Torquati A. Omental gene expression of adiponectin correlates with degree of insulin sensitivity before and after gastric bypass surgery. Obes Surg. 2012;22(3):472-7. doi: 10.1007/s11695-011-0568-xHaluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology. 2006;147(9):4517-24.Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology. 2006;147(9):4517-24.Dolezalova R, Lacinova Z, Dolinkova M, Kleiblova P, Haluzikova D, Housa D et al. Changes of endocrine function of adipose tissue in anorexia nervosa: comparison of circulating levels versus subcutaneous mRNA expression. Clin Endocrinol (Oxf). 2007;67(5):674-8.Dolezalova R, Lacinova Z, Dolinkova M, Kleiblova P, Haluzikova D, Housa D et al. Changes of endocrine function of adipose tissue in anorexia nervosa: comparison of circulating levels versus subcutaneous mRNA expression. Clin Endocrinol (Oxf). 2007;67(5):674-8.Behre CJ, GummessonA, Jernas M, Lystig TC, Fagerberg B, Carlsson B et al. Dissociation between adipose tissue expression and serum levels of adiponectin during and after diet-induced weight loss in obese subjects with and without the metabolic syndrome. Metabolism. 2007;56(8):1022-8.Behre CJ, GummessonA, Jernas M, Lystig TC, Fagerberg B, Carlsson B et al. Dissociation between adipose tissue expression and serum levels of adiponectin during and after diet-induced weight loss in obese subjects with and without the metabolic syndrome. Metabolism. 2007;56(8):1022-8.Andersen PH, Kristensen K, Pedersen SB, Hjollund E, Schmitz O, Richelsen B. Effects of long-term total fasting and insulin on ob gene expression in obese patients. Eur J Endocrinol. 1997;137(3):229-33.Andersen PH, Kristensen K, Pedersen SB, Hjollund E, Schmitz O, Richelsen B. Effects of long-term total fasting and insulin on ob gene expression in obese patients. Eur J Endocrinol. 1997;137(3):229-33.Ranganathan S, Maffei M, Kern PA. Adipose tissue ob mRNA expression in humans: discordance with plasma leptin and relationship with adipose TNFalpha expression. J Lipid Res. 1998;39 (4):724-30.Ranganathan S, Maffei M, Kern PA. Adipose tissue ob mRNA expression in humans: discordance with plasma leptin and relationship with adipose TNFalpha expression. J Lipid Res. 1998;39 (4):724-30.Wang ZV, Schraw TD, Kim JY, Khan T, Rajala MW, Follenzi A et al. Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol. 2007;27(10):3716-31.Wang ZV, Schraw TD, Kim JY, Khan T, Rajala MW, Follenzi A et al. Secretion of the adipocyte-specific secretory protein adiponectin critically depends on thiol-mediated protein retention. Mol Cell Biol. 2007;27(10):3716-31.Russell CD, Ricci MR, Brolin RE, Magill E, Fried SK. Regulation of the leptin content of obese human adipose tissue. Am J Physiol Endocrinol Metab. 2001;280(3):E399-404.Russell CD, Ricci MR, Brolin RE, Magill E, Fried SK. Regulation of the leptin content of obese human adipose tissue. Am J Physiol Endocrinol Metab. 2001;280(3):E399-404.

The authors declare that there are no conflicts of interest present.